Preview

Сибирский онкологический журнал

Расширенный поиск

ПОЗИТРОНАЯ ЭМИССИОНАЯ ТОМОГРАФИЯ В ОНКОГИНЕКОЛОГИИ

Полный текст:

Аннотация

Представленный обзор литературы посвящен анализу радиофармацевтических препаратов и эффективности применения позитронной эмиссионной томографии (ПЭТ) для диагностики, оценки распространенности и оценки эффективности злокачественных
новообразований женских половых органов. На основании результатов клинических исследований продемонстрированы диагностические возможности ПЭТ с  18F-фтордезоксиглюкозой в определении первичного опухолевого очага, оценке распространенности опухолевого процесса и эффективности противоопухолевого лечения при раке шейки и тела матки, яичников и вульвы.

Об авторах

Д. В. Рыжкова
ФГБУ «Российский научный центр радиологии и хирургических технологий» Министерства здравоохранения России, г. Санкт-Петербург
Россия


В. Л. Винокуров
ФГБУ «Российский научный центр радиологии и хирургических технологий» Министерства здравоохранения России, г. Санкт-Петербург
Россия


В. С. Павлова
ФГБУ «Федеральный центр сердца, крови и эндокринологии им. В. А. Алмазова» Министерства здравоохранения России, г. Санкт-Петербург
Россия


Ь. В. Рогачев
ФГБУ «НИИ онкологии им. Н.Н. Петрова» Министерства здравоохранения России, г. Санкт-Петербург
Россия


Список литературы

1. Гранов А.М., Тютин Л.А. Позитронная эмиссионная томография. СПб.: Фолиант, 2008. 368 с.

2. Belhocine T., De Barsy C., Hustinx R., Willems-Foidart J. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma // Eur. J. Nucl. Med. Mol. Imaging. 2002. Vol. 29. P. 1132–1139.

3. Benedet J.L., Bender H., Jones H. et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancer // Int. J. Gynecol. Obstet. 2000. Vol. 70. P. 209–262.

4. Bentivegna E., Uzan C., Gouy S. et al. The accuracy of FDG-PET/ CT in early-stage cervical and vaginal cancers // Gynecol. Obstet. Fertil. 2011. Vol. 39 (4). P. 193–197.

5. Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2005.

6. Chander S., Meltzer C.C., McCook B.M. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography // Clin. Nucl. Med. 2002. Vol. 27. P. 22–24.

7. Chang T.C., Law K.S., Hong J.H. et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study // Cancer. 2004. Vol. 101. P. 164–171.

8. Cohn D.E., Dehdashti F., Gibb R.K. et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer // Gynecol. Oncol. 2002. Vol. 85. P. 179–184.

9. Dehdashti F., Grigsby P.W., Mintun M.A. et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 62Cu-ATSM: relationship to therapeutic response – a preliminary report // Int. J. Radiat. Oncol. Biol. Phys. 2003. Vol. 55. P. 1233–1238.

10. Delbeke D., Martin W.H. Positron emission tomography imaging in oncology // Radiol. Clin. North. Am. 2001. Vol. 39. P. 883–917.

11. Drieskens O., Stroobants S., Gysen M. et al. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer // Gynecol. Obstet. Invest. 2003. Vol. 55. P. 130–134.

12. Grigsby P.W., Siegel B.A., Dehdashti F. et al. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome // J. Clin. Oncol. 2004. Vol. 22. P. 2167–2171.

13. Grit K., Horn L.C., Fisher U. et al. 18F-FDG positronen-Emissions-Tomographie bei Zervixkarzinom: Erste Ergebnisse // Zbl. Gynacol. 2001. № 4. P. 123.

14. Gorospe L., Jover-Diaz R., Vicente-Bartulos A. et al Spectrum of PET-CT pelvic pitfalls in patients with gynecologic malignancies // Abdom. Imaging. 2012. Vol. 37 (6). P. 1041–1065.

15. Havrilesky L.J., Kulasingam S.L., Matchar D.B., Myers E.R. FDGPET for management of cervical and ovarian cancer // Gynecol. Oncol. 2005. Vol. 97. P. 183–191.

16. Hubner K.F., McDonald T.W., Niethammer J.G. et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[ 18F]deoxyglucose (2-[ 18F]FDG) // Gynecol Oncol. 1993. Vol. 51. P. 197–204.

17. Hughes E.C. The effect of enzymes upon metabolism, storage and release of carbohydrates in normal and abnormal endometria // Cancer. 1976. Vol. 38. P. 487–502.

18. Jang H.J., Lee K.H., Kim Y.H. et al. The role PET for predicting prognosis in squamous cell type uterine cervical carcinoma patients // J. Nucl. Med. 2002. Vol. 43 (3). Suppl. P. 28.

19. Kim S., Chung J.K., Kang S.B. et al. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma // Eur. J. Nucl. Med. Mol. Imaging. 2004. Vol. 31. P. 196–201.

20. Lai C.H., Huang K.G., See L.C. et al. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography // Cancer. 2004. Vol. 100. P. 544–552.

21. Lamoreaux W.T., Grigsby P.W., Dehdashti F. et al. FDG-PET evaluation of vaginal carcinoma // Int. J. Radiat. Oncol. Biol. Phys. 2005. Vol. 62. P. 733–737.

22. Lapela M., Leskinen-Kallio S., Varpula M. et al. Imaging of uterine carcinoma by carbon-11-methionine and PET // J. Nucl. Med. 1994. Vol. 35. P. 1618–1623.

23. Lerman H., Metser U., Grisaru D. et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT // J. Nucl. Med. 2004. Vol. 45. P. 266–271.

24. Ma S.Y., See L.C., Lai C.H. et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients // J. Nucl. Med. 2003. Vol. 44. P. 1775–1783.

25. Nanni C., Rubello D., Farsad M. et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients // Eur. J. Surg. Oncol. 2005. Vol. 31. P. 792–797.

26. Park W., Park Y.J., Huh S.J. et al. The usefulness of MRI and PET imaging for the Detection of parametrial involvement and lymph node metastasis in patients with cervical cancer // Jpn. J. Clin. Oncol. 2005. Vol. 35. P. 260–264.

27. Picchio M., Sironi S., Messa C. et al. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment // J. Nucl. Med. 2003. Vol 47. P. 77–84.

28. Rose P.G., Faulhaber P., Miraldi F., Abdul-Karim F.W. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy // Gynecol. Oncol. 2001. Vol. 82. P. 17–21.

29. Saga T., Higashi T., Ishimori T. et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer // Ann. Nucl. Med. 2003. Vol. 17. P. 197–203.

30. Schroder W., Zimmy M., Rudlowski C. et al. The role of 18-fluorodeoxyglucose positron emission tomography in diagnosis of ovarian cancer // Int. J. Gynecol. Cancer. 1999. Vol. 9. P. 117–122.

31. Schroder W., Zimny M., Rudlowski C. The role of 18-F-flurorodeoxyglucose position imaging tomography 18-F-FGD PET in ovarian carcinoma // Int. J. Gynecol. Cancer. 1999. Vol. 9. P. 117–122.

32. Singh A.K., Grigsby P.W., Dehdashti F. et al. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma // Int. J. Radiat. Oncol. Biol. Phys. 2003. Vol. 56. P. 489–493.

33. Smith G.T., Hubner K.F., McDonald T., Thie J.A. Cost analysis of FDG PET for managing patients with ovarian cancer // Clin. Positron Imaging. 1999. Vol. 2. P. 63–70.

34. Son H., Khan S.M., Rahaman J. Role of FDG PET/CT in Staging of Recurrent Ovarian Cancer // J. RadioGraphics. 2011. Vol. 31. P. 569–583.

35. Son H., Kositwattanarerk A., Hayes M.P. et al. PET/CT Evaluation of Cervical Cancer: Spectrum of Disease // J. RadioGraphics. 2010. Vol. 30. P. 1251–1268.

36. Takekuma M., Maeda M., Ozawa T. et al. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer // Int. J. Clin. Oncol. 2005. Vol. 10. P. 177–181.

37. Tjalma W.A., Carp L., De Beeck B.O. False-positive positron emission tomographic scan and computed tomography for recurrent vaginal cancer: pitfalls of modern imaging techniques // Gynecol. Oncol. 2004. Vol. 92. P. 726–728.

38. Torizuka T., Kanno T., Futatsubashi M., et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET // J. Nucl. Med. 2003. Vol. 44. P. 1051–1056.

39. Turlakow A., Yeung H.W., Salmon A.S. et al. Peritoneal carcinomatosis: role of (18)F-FDG PET // J. Nucl. Med. 2003. Vol. 44. P. 1407–1412.

40. Umesaki N., Tanaka T., Miyama M. et al. Positron emission tomography using 2-[(18)F] fluoro-2-deoxy-D-glucose in the diagnosis of uterine leiomyosarcoma: a case report // Clin. Imaging. 2001. Vol. 25. P. 203–205.

41. Umesaki N., Tanaka T., Miyama M. et al. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging // Gynecol. Oncol. 2001. Vol. 80. P. 372–377.

42. Viswanathan A., Kirisits C., Erickson B.E., Pötter R. Gynecologic Radiation Therapy – Novel Approaches to Image-Guidance and Management. Springer Verlag, 2010. 308 p.

43. Wong T.Z., Jones E.L., Coleman R.E. Positron emission tomography with 2-eoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer // Mol. Imaging Biol. 2004. Vol. 6. P. 55–62.

44. Yen T.C., Lai C.H., Wu Y.H. et al. Glut-1 expression in invasive cervical cancer // Eur. J. Nucl. Med. Mol. Biol. 2002. Vol. 29 (Suppl). P. 266.

45. Yen T.C., See L.C., Chang T.C. et al. Defining the priority of using 18F-FDG PET for recurrent cervical cancer // J. Nucl. Med. 2004. Vol. 45. P. 1632–1639.


Для цитирования:


Рыжкова Д.В., Винокуров В.Л., Павлова В.С., Рогачев Ь.В. ПОЗИТРОНАЯ ЭМИССИОНАЯ ТОМОГРАФИЯ В ОНКОГИНЕКОЛОГИИ. Сибирский онкологический журнал. 2013;(2):77-83.

For citation:


Ryzhkova D.V., Vinokurov V.L., Pavlova V.S., Rogachev M.V. POSITRON EMISSION TOMOGRAPHY IN GYNECOLOGIC ONCOLOGY. Siberian journal of oncology. 2013;(2):77-83. (In Russ.)

Просмотров: 204


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1814-4861 (Print)
ISSN 2312-3168 (Online)